Martek maintained at neutral by Merrill

Martek Biosciences Corp. was maintained by Merrill Lynch analyst David Munno at a neutral rating on news that Odwalla, a subsidiary of Coke, would launch a line of soy milk products containing Martek's DHA. While maybe not the blockbuster deal some expected, the deal may allow Martek a foothold with Coke for future products. Merrill believes the revenue potential from the Coke deal will be small, $3 million to $7 million from soy milk and $23 million from Coke's juice brands. Shares of the Columbia, Md., biotechnology company were up 50 cents, or 1.52%, at $33.50 on volume of 866,672 shares versus the three-month running average of 1,028,010 shares. (Nasdaq: MATK)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.